Choosing Appropriate Estimands in Clinical Trials

被引:0
作者
Ann-Kristin Leuchs
Jörg Zinserling
Andreas Brandt
Dorothee Wirtz
Norbert Benda
机构
[1] Federal Institute for Drugs and Medical Devices (BfArM),
来源
Therapeutic Innovation & Regulatory Science | 2015年 / 49卷
关键词
clinical trials; estimands; efficacy; effectiveness; nonadherence; missing data;
D O I
暂无
中图分类号
学科分类号
摘要
Lack of adherence to study protocol and missing data are often unavoidable in clinical trials, and both increase the need to differentiate between the ideal treatment effect if the medication is taken as directed and the treatment effect in presence of the actual adherence pattern. In this regard, estimands have become the focus of attention. An estimand is simply that which is being estimated. In the context of treatment benefit, an estimand may address either efficacy or effectiveness aspects. Defining the estimand of interest is an essential step to take before deciding on trial design and primary analysis. The choice of estimand has consequences for various other factors to be considered during any clinical trial’s planning phase. This study presents a process chart including all aspects to consider during planning. After deciding on the primary estimand, the trial design should be specified, followed by the primary analysis. Both should appropriately address the chosen estimand. Finally, sensitivity analyses should be taken into account. Provided are suggestions for all the planning steps involved, especially on choosing between efficacy and effectiveness, and relevant examples from clinical practice to illustrate them. It is recommended that one bear in mind the process chart during planning of any clinical trial and give reasonable justification for each decision in the study protocol.
引用
收藏
页码:584 / 592
页数:8
相关论文
共 65 条
  • [1] Molenberghs G(2009)Incomplete data in clinical studies: analysis, sensitivity, and sensitivity analysis Drug Inf J 43 409-429
  • [2] Mallinckrodt CH(2014)Recent developments in the prevention and treatment of missing data Therapeutic Innovation & Regulatory Science 48 68-80
  • [3] Roger J(2012)The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it Clin Pharmacol Ther 91 550-554
  • [4] Chuang-Stein C(2013)The handling of missing data in clinical trials Clin Invest 3 241-250
  • [5] O’Neill RT(2009)Conceptual considerations regarding endpoints, hypotheses, and analyses for incomplete longitudinal clinical trial data Drug Inf J 43 449-458
  • [6] Temple R(2013)Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation J Biopharm Stat 23 1352-1371
  • [7] Kenward MG(2012)A structural approach to choosing estimands and estimators in longitudinal clinical trials Pharm Stat 11 456-461
  • [8] Mallinckrodt CH(2011)Addressing missing data in clinical trials Ann Internal Med 154 113-117
  • [9] Kenward MG(1993)Some conceptual and statistical issues in analysis of longitudinal psychiatric data Arch Gen Psychiatry 50 739-750
  • [10] Carpenter JR(2001)Type 1 error rates from mixed effects model repeated measures versus fixed effects ANOVA with missing values imputed via last observation carried forward Drug Inf J 35 1215-1225